Granted Patent
B2
US 12,565,651 · App. 18/768,373 · Granted Mar 3, 2026
Oligonucleotides comprising segmented gap structures
Assignee:
AUSPERBIO THERAPEUTICS INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are modified oligonucleotides complementary to a portion of a Hepatitis B virus (HBV) genome, wherein the modified oligonucleotides comprise a 5′ wing segment, a first gap segment, a first separator segment comprising a 2′ sugar modification, a second gap segment, and a 3′ wing segment. Such modified oligonucleotides are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.
Claims (7)
1 . A modified oligonucleotide complementary to a portion of a Hepatitis B virus (HBV) genome, wherein the modified oligonucleotide comprises SEQ ID NO: 456 .
2 . The modified oligonucleotide of claim 1 , wherein at least one internucleoside linkage is a phosphodiester linkage.
3 . The modified oligonucleotide of claim 1 , wherein the modified oligonucleotide is linked to a conjugate group.
4 . The modified oligonucleotide of claim 1 , wherein the modified oligonucleotide is linked to a stabilizing group.
5 . The modified oligonucleotide of claim 1 , wherein at least one internucleoside linkage is a modified internucleoside linkage.
6 . The modified oligonucleotide of claim 5 , wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.
7 . The modified oligonucleotide of claim 1 , wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.
Assignments (2)
NUNC PRO TUNC ASSIGNMENT
Recorded Jul 25, 2025
From: AUSPER BIOPHARMA CO., LTD.
To: AUSPERBIO THERAPEUTICS INC.
Reel/Frame 071835/0434 →
NUNC PRO TUNC ASSIGNMENT
Recorded Jul 25, 2025
From: CHENG, GUOFENG; YANG, CHENG YONG
To: AUSPER BIOPHARMA CO., LTD.
Reel/Frame 071835/0426 →
Continuity (3)
Continuation
PCTCN2023000030
· Jan 10, 2023
Provisional Application
63298092
· Jan 10, 2022
References Cited (172)
US 4522811A
· Eppstein et al.
· 1985
[cited by applicant]
US 6268490B1
· Imanishi et al.
· 2001
[cited by applicant]
US 6525191B1
· Ramasamy
· 2003
[cited by applicant]
US 6670461B1
· Wengel et al.
· 2003
[cited by applicant]
US 6770748B2
· Imanishi et al.
· 2004
[cited by applicant]
US 6794499B2
· Wengel et al.
· 2004
[cited by applicant]
US 7034133B2
· Wengel et al.
· 2006
[cited by applicant]
US 7053207B2
· Wengel
· 2006
[cited by applicant]
US 7399845B2
· Seth et al.
· 2008
[cited by applicant]
US 7427672B2
· Imanishi et al.
· 2008
[cited by applicant]
US 7741457B2
· Seth et al.
· 2010
[cited by applicant]
US 7759479B1
· Dobie et al.
· 2010
[cited by applicant]
US 7919472B2
· Monia et al.
· 2011
[cited by applicant]
US 8501805B2
· Seth et al.
· 2013
[cited by applicant]
US 8530640B2
· Seth et al.
· 2013
[cited by applicant]
US 8541388B2
· Monia et al.
· 2013
[cited by applicant]
US 8546556B2
· Seth et al.
· 2013
[cited by applicant]
US 8642752B2
· Swayze et al.
· 2014
[cited by applicant]
US 8987435B2
· Swayze et al.
· 2015
[cited by applicant]
US 9145558B2
· Prakash et al.
· 2015
[cited by applicant]
US 9550988B2
· Swayze
· 2017
[cited by applicant]
US 9650636B2
· Freier et al.
· 2017
[cited by applicant]
US 9732344B2
· Beigelman et al.
· 2017
[cited by applicant]
US 9943604B2
· Seth et al.
· 2018
[cited by applicant]
US 20070299027A1
· Hung et al.
· 2007
[cited by applicant]
US 20080039618A1
· Allerson et al.
· 2008
[cited by applicant]
US 20120295961A1
· Swayze et al.
· 2012
[cited by applicant]
US 20170145424A1
· Prakash et al.
· 2017
[cited by applicant]
US 20200385714A1
· Hagedorn et al.
· 2020
[cited by applicant]
US 20200407717A1
· Wang et al.
· 2020
[cited by applicant]
US 20220339281A1
· Bayat
· 2022
[cited by examiner]
US 20220380761A1
· Oerum et al.
· 2022
[cited by applicant]
US 20240299534A1
· Cheng et al.
· 2024
[cited by applicant]
US 20250215430A1
· Cheng et al.
· 2025
[cited by applicant]
AU 2017201608A1
· 2017
[cited by applicant]
CA 3094303A1
· 2019
[cited by examiner]
CN 105378085A
· 2016
[cited by applicant]
CN 111344408A
· 2020
[cited by applicant]
CN 111868245A
· 2020
[cited by applicant]
CN 113573730A
· 2021
[cited by applicant]
CN 114846140A
· 2022
[cited by applicant]
CN 118667808A
· 2024
[cited by applicant]
EP 2742056B1
· 2017
[cited by applicant]
EP 3556859B1
· 2021
[cited by applicant]
WO WO9414226A1
· 1994
[cited by applicant]
WO WO9839352A1
· 1998
[cited by applicant]
WO WO9914226A2
· 1999
[cited by applicant]
WO WO03004602A2
· 2003
[cited by applicant]
WO WO2004106356A1
· 2004
[cited by applicant]
WO WO2005021570A1
· 2005
[cited by applicant]
WO WO2007134181A2
· 2007
[cited by applicant]
WO WO2008101157A1
· 2008
[cited by applicant]
WO WO2008150729A2
· 2008
[cited by applicant]
WO WO2008154401A2
· 2008
[cited by applicant]
WO WO2009006478A2
· 2009
[cited by applicant]
WO WO2009148605A2
· 2009
[cited by applicant]
WO WO2011047312A1
· 2011
[cited by applicant]
WO WO2012109395A1
· 2012
[cited by applicant]
WO WO2012145697A1
· 2012
[cited by applicant]
WO WO2013022966A1
· 2013
[cited by applicant]
WO WO2013022967A1
· 2013
[cited by applicant]
WO WO2013022984A1
· 2013
[cited by applicant]
WO WO2013022990A1
· 2013
[cited by applicant]
WO WO2014179620A1
· 2014
[cited by applicant]
WO WO2015021457A2
· 2015
[cited by applicant]
WO WO2015173208A2
· 2015
[cited by applicant]
WO WO2020178359A1
· 2020
[cited by applicant]
WO WO2022100744A1
· 2022
[cited by applicant]
WO WO2023083906A2
· 2023
[cited by applicant]
WO WO2023131098A2
· 2023
[cited by applicant]
WO WO2023131926A2
· 2023
[cited by applicant]
WO WO2023144750A1
· 2023
[cited by applicant]
WO WO2023187612A1
· 2023
[cited by applicant]
WO WO2023194537A1
· 2023
[cited by applicant]
WO WO2024149282A1
· 2024
[cited by applicant]
WO WO2024221135A1
· 2024
[cited by applicant]
WO WO2024222647A1
· 2024
[cited by applicant]
WO WO2025242158A1
· 2025
[cited by applicant]
Inoue H, et al., FEBS Lett. May 11, 1987;215(2):327-30 (Year: 1987).
[cited by examiner]
Albaek et al., “Analogues of a locked nucleic acid with three-carbon 2′,4′-linkages: synthesis by ring-closing metathesis and influence on nucleic acid duplex stability and structure” J Org Chem. Sep. 29, 2006; 71(20):7…
[cited by applicant]
Altmann et al., “Second Generation Antisense Oligonucleotides—Inhibition of PKC-α and c-raf Kinase Expression by Chimeric Oligonucleotides Incorporating 6″-Substituted Carbocyclic Nucleosides and 2″-O-Ethylene Glycol Su…
[cited by applicant]
Altmann et al., “Second Generation of Antisense Oligonucleotides: From Nuclease Resistance to Biological Efficacy in Animals” Chimia (1996) 50:168-176.
[cited by applicant]
Altmann et al., “Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors” Biochem Soc Trans. Aug. 1996; 24(3):630-637.
[cited by applicant]
Baker et al., “2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation comple…
[cited by applicant]
Braasch et al., “Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA” Chem Biol. Jan. 2001; 8(1):1-7.
[cited by applicant]
Chattopadhyaya et al., “Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2′,4′-carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties” J O…
[cited by applicant]
Chulanov et al., “Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses” J Med Virol. Mar. 2003; 69(3):313-323.
[cited by applicant]
Cote et al., “Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection” Hepatology. Jan. 2000; 31(1):190-200.
[cited by applicant]
Den Brouw et al., “Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus” Immunology. (2008) 126(2):280-289.
[cited by applicant]
Elayadi et al., “Application of PNA and LNA oligomers to chemotherapy” Curr Opin Investig Drugs. Apr. 2001; 2(4):558-561.
[cited by applicant]
Evans et al., “Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion” Hepatology. Sep. 2008; 48(3):759-769.
[cited by applicant]
Freier et al., “The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes” Nucleic Acids Res. Nov. 15, 1997; 25(22):4429-4443.
[cited by applicant]
Fried et al., “HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B” Hepatology. Feb. 2008; 47(2):428-434.
[cited by applicant]
Frieden et al., “Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA” Nucleic Acids Res. Nov. 1, 2003; 31(21):6365-6372.
[cited by applicant]
Ganem et al., “Hepatitis B virus infection—natural history and clinical consequences” N Engl J Med. Mar. 11, 2004; 350(11):1118-1129.
[cited by applicant]
Gautschi et al., “Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins” J Natl Cancer Inst. Mar. 21, 2001; 93(6):463-471.
[cited by applicant]
GenBank Accession No. AB033550.1, Oct. 19, 1999, 3 pages.
[cited by applicant]
GenBank Accession No. AJ309369.1, Aug. 15, 2001, 3 pages.
[cited by applicant]
GenBank Accession No. D00330.1, Jul. 20, 2007, 2 pages.
[cited by applicant]
GenBank Accession No. KP718112, Aug. 19, 2015, 3 pages.
[cited by applicant]
GenBank Accession No. KX186584, Aug. 26, 2016, 3 pages.
[cited by applicant]
GenBank Accession No. KX264500, May 31, 2016, 3 pages.
[cited by applicant]
GenBank Accession No. KX264501, May 31, 2016, 3 pages.
[cited by applicant]
GenBank Accession No. KX470733.1, Aug. 31, 2016, 6 pages.
[cited by applicant]
GenBank Accession No. NM_000295.5, Aug. 12, 2024, 6 pages.
[cited by applicant]
GenBank Accession No. NM_000371.4, Aug. 19, 2024, 4 pages.
[cited by applicant]
GenBank Accession No. NM_004409.5, Aug. 4, 2024, 5 pages.
[cited by applicant]
GenBank Accession No. NM_013697.5, Jul. 30, 2024, 4 pages.
[cited by applicant]
GenBank Accession No. NM_174936.4, Jul. 23, 2024, 6 pages.
[cited by applicant]
GenBank Accession No. NP_000286.3, Aug. 12, 2024, 4 pages.
[cited by applicant]
GenBank Accession No. NP_000362.1, Aug. 19, 2024, 3 pages.
[cited by applicant]
GenBank Accession No. NP_004400.4, Aug. 4, 2024, 4 pages.
[cited by applicant]
GenBank Accession No. NP_777596.2, Jul. 23, 2024, 4 pages.
[cited by applicant]
GenBank Accession No. U95551.1, Jun. 7, 1997, 3 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/CN2023/000030 dated Aug. 23, 2023, 16 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/CN2023/106924 dated Apr. 2, 2024, 15 pages.
[cited by applicant]
International Search Report and Written Opinion mailed on Apr. 1, 2024, for International Application No. PCT/CN2024/071514, 19 pages.
[cited by applicant]
International Search Report and Written Opinion mailed on Jun. 28, 2023, for International Application No. PCT/IB2023/050207, filed on Jan. 10, 2023, 14 pages.
[cited by applicant]
Invitation to Pay Addiitonal Fees and, Where Applicable, Protest Fee mailed on Dec. 15, 2023, 2023, for International Application No. PCT/CN2023/106924, filed on Jul. 12, 2023, 2 pages.
[cited by applicant]
Invitation to Pay Fee for International Application No. PCT/CN2023/000030 dated Jun. 1, 2023, 2 pages.
[cited by applicant]
Javanbakht H., et al. “Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo” Mol Ther Nucleic Acids, vol. 11 , Feb. 23, 2018 (Feb. 23, 2018), 441-…
[cited by applicant]
Karlin et al., “Applications and statistics for multiple high-scoring segments in molecular sequences” PNAS USA (1993) 90:5873-5877.
[cited by applicant]
Koshkin et al., “LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition” Tat…
[cited by applicant]
Kumar et al., “The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2′-thio-LNA” Bioorg Med Chem Lett. Aug. 18, 1998; 8(16):2219-2222.
[cited by applicant]
Leumann, “DNA analogues: from supramolecular principles to biological properties” Bioorg Med Chem. Apr. 2002; 10(4):841-854.
[cited by applicant]
Liang et al., “Hepatitis B e Antigen—the dangerous endgame of hepatitis B” N Engl J Med. Jul. 18, 2002; 347(3):208-210.
[cited by applicant]
Maher and Dolnick, “Comparative hybrid arrest by tandem antisense oligodeoxyribonucleotides or oligodeoxyribonucleoside methylphosphonates in a cell-free system” Nucleic Acids Res. Apr. 25, 1988; 16(8):3341-3358.
[cited by applicant]
Martin, “Ein neuer Zugang zu 2′-O-Alkylribonucleosiden und Eigenschaften deren Oligonucleotide” Helv. Chim. Acta (1995) 78:486-504.
[cited by applicant]
Milich et al., “The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence” J Immunol. Feb. 15, 1998; 160(4):2013-2021.
[cited by applicant]
Moucari et al., “Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients” Hepatology. Apr. 2009; 49(4):1151-1157.
[cited by applicant]
Orum et al., “Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development” Curr Opin Mol Ther. Jun. 2001; 3(3):239-243.
[cited by applicant]
Reignat et al., “Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection” J Exp Med. May 6, 2002; 195(9):1089-1101.
[cited by applicant]
Rukov et al., “Dissecting the target specificity of RNase H recruiting oligonucleotides using massively parallel reporter analysis of short RNA motifs” Nucleic Acids Res. Sep. 30, 2015; 43(17):8476-8487.
[cited by applicant]
Seeger et al., “Hepatitis B virus biology” Microbiol Mol Biol Rev. Mar. 2000; 64(1):51-68.
[cited by applicant]
Singh et al., “LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition” Chem. Commun. (1998) 4:455-456.
[cited by applicant]
Singh et al., “Synthesis of 2′-Amino-LNA: A Novel Conformationally Restricted High-Affinity Oligonucleotide Analogue with a Handle” J. Org. Chem. (1998) 63:10035-10039.
[cited by applicant]
Srivastava et al., “Five- and six-membered conformationally locked 2′,4′-carbocyclic ribo-thymidines: synthesis, structure, and biochemical studies” J Am Chem Soc. Jul. 4, 2007; 129(26):8362-8379.
[cited by applicant]
Tarn et al., “Antisense Oligonucleotide-Based Therapy of Viral Infections” Pharmaceutics. Nov. 26, 2021; 13(12):2015. 18 pages.
[cited by applicant]
Terazawa et al., “Hepatitis B virus mutants with precore-region defects in two babies with fulminant hepatitis and their mothers positive for antibody to hepatitis B e antigen” Pediatr Res. Jan. 1991; 29(1):5-9.
[cited by applicant]
Wahlestedt et al., “Potent and nontoxic antisense oligonucleotides containing locked nucleic acids” PNAS USA (2000) 97:5633-5638.
[cited by applicant]
Woolf et al., “Specificity of antisense oligonucleotides in vivo” PNAS USA (1992) 89:7305-7309.
[cited by applicant]
Yuen M., et al., “Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial,” Nature Medicine, 2021, vol. 27(10…
[cited by applicant]
Zheng et al., “Selective functional deficit in dendritic cell—T cell interaction is a crucial mechanism in chronic hepatitis B virus infection” J Viral Hepat. May 2004; 11(3):217-224.
[cited by applicant]
Zhu, X., et al., “The difference of anti-virus effect between different modified antisense oligonucleotides in vitro” Chin J Hepatol, vol. 21, No. 6, Jun. 30, 2013, 475-476.
[cited by applicant]
U.S. Appl. No. 18/727,839, filed Jul. 10, 2024, by Cheng et al.
[cited by applicant]
EP Application No. 23736963.2, Partial Supplementary European Search Report mailed Nov. 17, 2025; Applicant AusperBio Therapeutics Inc.; 20 pages.
[cited by applicant]
Gupta et al., “Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection” Drugs in R&D Nov. 2021; 21(4):455-465.
[cited by applicant]
PCT Application No. PCT/CN2025/096518, International Search Report and Written Opinion mailed Aug. 31, 2025; Applicant AusperBio Therapeutics, Inc.; 12 pages.
[cited by applicant]
Sandra et al., “Plasma and Liver Pharmacokinetics of the N-Acetylgalactosamine Short Interfering RNA JNJ-73763989 in Recombinant Adeno-Associated-Hepatitis B Virus-Infected Mice” The Journal of Pharmacology and Experime…
[cited by applicant]
Tan et al., “Combination drug interactions of hepatitis B virus (HBV) small interfering RNA (siRNA) and antisense oligonucleotides (ASO) in vitro and in vivo” The Journal of Hepatology Dec. 2021, 75(2):S720, 1 page.
[cited by applicant]
U.S. Appl. No. 19/146,769, filed Jul. 9, 2025; Inventor Cheng, Guofeng et al.
[cited by applicant]
U.S. Appl. No. 19/366,428, filed Oct. 22, 2025; Inventor Cheng, Guofeng et al.
[cited by applicant]
PCT Application No. PCT/CN2025/096518, filed May 22, 2025; Applicant AusperBio Therapeutics, Inc.; 110 pages.
[cited by applicant]
Hill et al., “The MOE Modification of RNA: Origins and Widescale Impact on the Oligonucleotide Therapeutics Field” Helvetica Chimica Acta Mar. 2023; 106(3):e202200169, 15 pages.
[cited by applicant]
Stein et al., “Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents” Nucleic Acids Res. Jan. 2010; 38(1):e3, 8 pages.
[cited by applicant]